Robotic Surgery Faster for Laparoscopy in Endometrial CA

Share this content:
Robotic Surgery Faster for Laparoscopy in Endometrial CA
Robotic Surgery Faster for Laparoscopy in Endometrial CA

THURSDAY, Nov. 3, 2016 (HealthDay News) -- For patients with endometrial cancer, robotic-assisted laparoscopic surgery is faster than traditional surgery, according to a study published in the November issue of the American Journal of Obstetrics & Gynecology.

Minna M. Mäenpää, M.D., from Tampere University Hospital in Finland, and colleagues compared traditional and robotic-assisted laparoscopic surgery for endometrial cancer in a randomized controlled trial. One hundred one endometrial cancer patients were randomly allocated to hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy by robotic-assisted laparoscopic surgery or traditional laparoscopy; 99 patients were eligible for analysis.

The researchers found that the median operation time was 170 minutes in the traditional laparoscopy group and 139 minutes in the robotic surgery group (P < 0.001). The robotic surgery group also had a shorter total time spent in the operating room than the traditional group (197 versus 228 minutes; P < 0.001). There were five conversions to laparotomy in the traditional laparoscopy group versus none in the robotic surgery group (P = 0.027). The number of lymph nodes removed, bleeding, and length of postoperative hospital stay did not differ between the groups. There were no significant differences between the groups in intraoperative complications (P = 0.56) and major postoperative complications (P = 0.111).

"Robotic surgery offers an effective and safe alternative in the surgical treatment of endometrial cancer," the authors write.

One author spent four years as a proctor for robotic surgery.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »